Current stage-Stage II - Page 2 of 6 Posts on Medivizor
Navigation Menu

Current stage-Stage II Posts on Medivizor

Improving the tolerability of neratinib in patients with early-stage HER2-positive breast cancer.

Improving the tolerability of neratinib in patients with early-stage HER2-positive breast cancer.

Posted by on Aug 15, 2020 in Breast cancer | 0 comments

In a nutshell This trial evaluated strategies to improve diarrhea as a side effect of neratinib (Nerlynx) treatment in patients with HER2-positive breast cancer (BC). The authors showed that slowly increasing the doses of neratinib or taking anti-diarrhea medication can improve this side effect. Some background Neratinib (Nerlynx) is a targeted...

Read More

Long term effects of hypofractionated prone intensity-modulated radiation therapy after breast conservation surgery in patients with breast cancer

Long term effects of hypofractionated prone intensity-modulated radiation therapy after breast conservation surgery in patients with breast cancer

Posted by on Jul 12, 2020 in Breast cancer | 0 comments

In a nutshell The study evaluated long-term outcomes of combining hypofractionated intensity-modulated radiation therapy (H-IMRT) with prone-positioning in patients after conservation surgery for breast cancer. The authors found that this combination safely controlled cancer locally without affecting regional lymph nodes. Some background Adjuvant...

Read More

Searching for patients with locally advanced non-small cell lung cancer to test a chemoradiotherapy regimen

Posted by on May 28, 2019 in Lung cancer | 0 comments

In a nutshell This trial is examining the effectiveness and safety of standard chemoradiation vs a PET base chemoradiation combination in patients with non-small cell lung carcinoma (NSCLC). The main outcomes to be measured will be side effects and survival without cancer growing or spreading. The details A treatment option for...

Read More

Long-short radiation therapy before surgery is associated with better outcomes in stage 2 and 3 rectal cancer

Posted by on Apr 21, 2019 in Colorectal cancer | 0 comments

In a nutshell This study compared the survival outcomes of patients with rectal cancer who underwent short- or long-course radiation therapy (RT). Researchers suggested that long-course RT was associated with greater tumor response and survival. Some background Colorectal cancer is the third most common cancer diagnosed in the United States. The...

Read More

Lymphocyte count reduction is associated with better rectal cancer outcomes

Posted by on Jan 13, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the relationship between lymphocyte (a type of white blood cells) counts and treatment outcomes for patients with rectal cancer. Researchers suggested that lymphocyte count reduction may be caused by rectal cancer treatment and is associated with better tumor response. Some background Colorectal cancer is the...

Read More

Length of treatment with trastuzumab in HER2+ early stage breast cancer

Posted by on Jan 2, 2019 in Breast cancer | 0 comments

In a nutshell This study wanted to find out what the best length of treatment with trastuzumab (Herceptin) is for HER2+ early stage breast cancer. The study found that at least one year of treatment had the best results in terms of how well it worked, and the cost-effectiveness. Some background HER-2 positive breast cancer is a type of cancer where...

Read More

Surgical treatment options for anal melanoma

Posted by on Oct 9, 2018 in Melanoma | 0 comments

In a nutshell This study compared the afety and effectiveness of two surgical treatments for anal melanoma. The study found that patients who had a local excision and patients who had an abdominoperineal resection had the same level of overall survival. Some background Anal melanoma is a very rare cancer. Two surgical options for treatment are...

Read More